Stephen Lewis, MD
Interventional Cardiology · Cincinnati, OHNPI 1619970274
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,262 of the $7,377 with a category attached, or 71.3%. 34 manufacturers reported payments, led by Medtronic at 34.7% of the total. 2025 is the largest year on record at $2,131, 3.8 times the $562 reported in 2019.
Across 208 payments — averaging $35.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Stryker$840
- Novartis$609
- Boston Scientific$514
- Abiomed$492
- Johnson & Johnson$375
- plus $2K from 28 others
Across 4 payments — averaging $294.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1K
What the payments were for
- Travel & lodging$2,11529%
- Food & beverage$5,26271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 24 | $2,559 |
| Stryker | 1 | $840 |
| Novartis | 55 | $609 |
| Boston Scientific | 9 | $514 |
| Abiomed | 5 | $492 |
| Johnson & Johnson | 25 | $375 |
| Carlsmed, Inc. | 1 | $228 |
| Boehringer Ingelheim | 10 | $169 |
| Amarin Pharma, Inc. | 9 | $165 |
| Cardiovascular Systems Inc. | 3 | $156 |
| Pfizer | 9 | $152 |
| Amgen | 10 | $145 |
| AstraZeneca | 10 | $131 |
| Siemens Medical Solutions USA, Inc. | 2 | $131 |
| Bayer | 7 | $109 |
| Angiodynamics, Inc. | 1 | $100 |
| Kestra Medical Technology Services, Inc. | 4 | $87 |
| Edwards Lifesciences | 2 | $43 |
| Merck | 3 | $42 |
| Cardiva Medical, Inc. | 1 | $41 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $35 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $31 |
| Portola Pharmaceuticals, LLC | 2 | $26 |
| Inari Medical, Inc. | 1 | $25 |
| Osprey Medical Inc | 1 | $19 |
| Atricure, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Dynasplint Systems Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Cardinal Health 200 LLC | 1 | $14 |
| Scpharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$1,636
- MAKO$840
- Impella$425
- RESOLUTE ONYX$364
- aprevo$228
- ONYX FRONTIER$140
- MAMBA$130
- AVVIGO Guidance System$128
- Diamondback Coronary$115
- Integrity$114
- SPECT Symbia Evo$105
- AngioVac$100
How this compares
$7,377 in reported general payments places this provider in the 60th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 90 | $134,582 |
| XareltoRivaroxaban | 20 | $29,541 |
| EntrestoSacubitril/Valsartan | 16 | $27,166 |
| JardianceEmpagliflozin | 13 | $16,240 |
| Repatha SureclickEvolocumab | 11 | $14,900 |
| BrilintaTicagrelor | 11 | $9,158 |
| ClopidogrelClopidogrel Bisulfate | 176 | $1,782 |
| Atorvastatin Calcium | 165 | $1,767 |
| Amiodarone Hcl | 15 | $1,446 |
| Rosuvastatin Calcium | 88 | $1,366 |
| Metoprolol Succinate | 100 | $1,243 |
| Warfarin Sodium | 90 | $1,039 |
| Ezetimibe | 20 | $923 |
| Nitroglycerin | 114 | $920 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 79 | $911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $152 | $134,58290 claims |
| Johnson & JohnsonXarelto | $375 | $29,54120 claims |
| NovartisEntresto | $609 | $27,16616 claims |
| Boehringer IngelheimJardiance | $169 | $16,24013 claims |
| AstraZenecaBrilinta | $131 | $9,15811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Cincinnati
- Timothy HenryCincinnati$605K
- John CorlCincinnati$390K
- Santiago GarciaCincinnati$360K
- Joseph ChooCincinnati$224K
- Dean KereiakesCincinnati$139K
- Ian SarembockCincinnati$98K
- Puvi SeshiahCincinnati$81K
- Raviteja GuddetiCincinnati$68K
- Satya ShreenivasCincinnati$47K
- Amer SayedCincinnati$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.